PRNewsWire
01 Jun 2026, 07:50 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/gossamer-bio-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--goss-302786661.html
Read source
Story key points
2 claims · impact-rated
Gossamer Bio, Inc. (GOSS) is facing a class action lawsuit alleging it concealed facts and made misleading statements regarding its Phase 3 PROSERA study. — Allegations of data concealment in a Phase 3 clinical trial strike at the core value driver of a biotech company and create significant regulatory and legal risk.
-0.60The lawsuit alleges violations of the Securities Exchange Act of 1934 and SEC Rule 10b-5 during the class period of June 16, 2025, to February 20, 2026. — Securities litigation can lead to costly settlements and damages, adding financial uncertainty to the company's balance sheet.
-0.30Ticker attribution
Model heads
The company is being sued in a class action lawsuit for securities law violations.
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit alleging securities law violations and misleading statements regarding a Phase 3 study.
The company is being sued in a class action lawsuit for securities law violations.
No ticker relationship head found.
Impact vectors
4 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
2h ago
